Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Arcturus Therapeutics to post earnings of ($0.6804) per share and revenue of $8.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. The company had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. On average, analysts expect Arcturus Therapeutics to post ($3.48) EPS for the current fiscal year and ($3.59) EPS for the next fiscal year.
Arcturus Therapeutics Stock Up 1.0%
Shares of ARCT stock traded up $0.10 on Tuesday, reaching $9.59. The stock had a trading volume of 232,177 shares, compared to its average volume of 629,960. Arcturus Therapeutics has a 12 month low of $5.50 and a 12 month high of $17.96. The firm has a market capitalization of $272.41 million, a price-to-earnings ratio of -2.90 and a beta of 2.48. The firm’s 50-day moving average is $13.53 and its two-hundred day moving average is $9.00.
Analysts Set New Price Targets
Several research firms have issued reports on ARCT. BTIG Research dropped their price objective on Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, September 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Thursday, September 24th. Roth Capital reissued a “buy” rating and set a $41.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.29.
Get Our Latest Analysis on Arcturus Therapeutics
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.
The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.
Featured Stories
- Five stocks we like better than Arcturus Therapeutics
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
